Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
INTIInhibitor Therapeutics, Inc.
| Figure | INTIInhibitor Therapeutics, Inc.FY2021 · Dec |
|---|---|
| Revenue | $0.00 |
| Revenue, yoy | — |
| Net income | $3.30M |
| Net income, yoy | +1.2% |
| Net margin | — |
| Free cash flow | — |
| FCF margin | — |
| EPS, diluted | $0.02 |
Add another company.
Annual · FY2017–FY2021 · USD
From SEC EDGARSame fiscal periods, as filed